T1	Participants 781 813	All subjects completed the trial
T2	Participants 592 625	subjects with mild-to-moderate AD
T3	Participants 734 772	The subjects were followed for 1 year.
T4	Participants 1010 1078	One subject (10 mg/kg) experienced a mild hypersensitivity reaction.
T5	Participants 1079 1171	Another subject (0.1 mg/kg) demonstrated slight enlargement of a preexisting midbrain lesion
